Mithra Pharmaceuticals S.A. Logo

Mithra Pharmaceuticals S.A.

Biotech firm developing pharma for women's health: contraception, fertility, and menopause.

MITRA | BR

Overview

Corporate Details

ISIN(s):
BE0974283153 (+1 more)
LEI:
5493002FDD273HTEKK14
Country:
Belgium
Address:
Rue Saint-Georges 5, 4000 Liège
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mithra Pharmaceuticals S.A. is a biotechnology company dedicated to women's health. The company specializes in the development, manufacturing, and commercialization of proprietary and over-the-counter pharmaceutical products. Its core focus areas include contraception, fertility, and menopause. Mithra's mission is to transform the women's health sector by providing innovative new choices that aim to improve the overall quality of life for women.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-06-11 10:00
M&A Activity
2024-06-11_Mithra_Press-Release_Mithra sells to GR_EN-FS (003) (002)-PDF.pdf
English 179.8 KB
2024-06-11 10:00
M&A Activity
2024-06-11_Mithra_Press-Release_Mithra sells to GR_FR-FS-PDF.pdf
French 126.7 KB
2024-06-10 19:15
Legal Proceedings Report
2024-06-10_Mithra_Press-Release_Mithra files for bankruptcy AND sells to GR_EN.…
English 181.9 KB
2024-06-10 19:15
Legal Proceedings Report
2024-06-10_Mithra_Press-Release_Mithra files for bankruptcy AND sells to GR_FR.…
French 128.7 KB
2024-06-04 08:00
Legal Proceedings Report
2024-0~1.PDF
English 153.0 KB
2024-06-04 08:00
Legal Proceedings Report
2024-0~2.PDF
French 158.7 KB
2024-05-28 15:00
Pre-Annual General Meeting Information
2024-05-28_Mithra_Press-release_Mithra postpones its annual general meeting_EN.…
English 139.6 KB
2024-05-28 15:00
Pre-Annual General Meeting Information
2024-05-28_Mithra_Press-release_Mithra postpones its annual general meeting_FR.…
French 143.3 KB
2024-05-10 16:30
Regulatory Filings
2024-05-10_Mithra_Press-release_Additional patent protection NEXSTELLIS_EN.pdf
English 124.3 KB
2024-05-10 16:30
Regulatory Filings
2024-05-10_Mithra_Press-release_Additional patent protection NEXSTELLIS_FR.pdf
French 126.5 KB
2024-05-03 17:30
M&A Activity
2024-05-03_Mithra_Press-release_Mithra Announces Exclusive Negotiations and Fun…
English 142.7 KB
2024-05-03 17:30
Capital/Financing Update
2024-05-03_Mithra_Press-release_Mithra Announces Exclusive Negotiations and Fun…
French 145.9 KB
2024-04-30 10:30
Proxy Solicitation & Information Statement
2024-04-30_MITHRA_VOTING-BY-MAIL-FORM_AGO-MAY-2024_EN.pdf
English 141.0 KB
2024-04-30 10:30
Pre-Annual General Meeting Information
2024-04-30_MITHRA_AGENDA_AGO-MAY-2024_FR.pdf
French 143.1 KB
2024-04-30 10:30
Proxy Solicitation & Information Statement
2024-04-30_MITHRA_PROXY-FORM_AGO-MAY-2024_EN.pdf
English 145.2 KB

Automate Your Workflow. Get a real-time feed of all Mithra Pharmaceuticals S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mithra Pharmaceuticals S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mithra Pharmaceuticals S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-01-17 NOSHAQ SA Board Other 172,574 617,814.92 EUR
2022-11-17 NOSHAQ SA Board Other 172,574 1,052,701.40 EUR
2022-07-18 NOSHAQ SA Board Other 156,250 1,006,250.00 EUR
2022-05-13 NOSHAQ SA Board Other 156,250 1,239,062.50 EUR
2022-04-13 Gordenne Valérie Other Sell 8,500 87,380.00 EUR
2022-03-29 Fornieri Francesco Board Sell 100,000 1,312,000.00 EUR
2022-03-25 Fornieri Francesco Board Sell 35,893 486,530.57 EUR
2022-03-24 Fornieri Francesco Board Sell 15,657 219,536.19 EUR
2022-03-24 Fornieri Francesco Board Sell 2,818 39,452.00 EUR
2022-03-23 Fornieri Francesco Board Sell 12,525 178,230.75 EUR

Peer Companies

Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.